Angiotensin-Converting Enzyme Inhibitors and Parameters of Sarcopenia: Relation to Muscle Mass, Strength and Function: Data from the Berlin Aging Study-II (BASE-II).
Pharmacological options for the treatment of sarcopenia currently do not exist. However, off-label treatment options of some established drugs have been suggested.



The aim of this study was to assess differences in various muscle and physical performance parameters in relation to the intake of angiotensin-converting enzyme (ACE) inhibitors in a cohort of community-dwelling older people.



Eight hundred and thirty-eight participants from the Berlin Aging Study-II (BASE-II) were included. Appendicular lean mass was assessed with dual-energy X-ray absorptiometry and related to height and body mass index. Muscle strength was measured by grip strength and related to muscle mass (arm muscle quality) and functional status was assessed via the timed "Up and Go" test.



Users of ACE inhibitors had higher lean mass related to height but significantly lower lean mass related to body mass index (p = 0.001 for women and p < 0.0001 for men). Moreover, they exhibited lower arm muscle quality (p = 0.032 for women and p = 0.031 for men) and reported difficulties in climbing stairs more often than non-users (p = 0.014 for women and p = 0.004 for men). After adjustment for confounders, there were no significant differences regarding lean mass, arm muscle quality and the timed "Up and Go" test according to the use of ACE inhibitors.



In BASE-II, no positive relationship was found between the intake of ACE inhibitors and lean mass, strength, muscle quality or function. Moreover, remarkable differences between parameters of absolute and relative lean mass in relation to the use of ACE inhibitors became evident. Fat mass proved to be an important confounder and therefore muscle mass cannot be viewed irrespectively of whole body composition.
Charité Research Group on Geriatrics, Charité-Universitätsmedizin Berlin, Reinickendorfer Str. 61, Berlin, 13347, Germany.
Dominik
D
Spira
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jeremy
J
Walston
Charité Research Group on Geriatrics, Charité-Universitätsmedizin Berlin, Reinickendorfer Str. 61, Berlin, 13347, Germany.
Nikolaus
N
Buchmann
Charité Research Group on Geriatrics, Charité-Universitätsmedizin Berlin, Reinickendorfer Str. 61, Berlin, 13347, Germany.
Jivko
J
Nikolov
Charité Research Group on Geriatrics, Charité-Universitätsmedizin Berlin, Reinickendorfer Str. 61, Berlin, 13347, Germany.|Institute of Medical and Human Genetics, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Ilja
I
Demuth
Charité Research Group on Geriatrics, Charité-Universitätsmedizin Berlin, Reinickendorfer Str. 61, Berlin, 13347, Germany.
Elisabeth
E
Steinhagen-Thiessen
Charité Research Group on Geriatrics, Charité-Universitätsmedizin Berlin, Reinickendorfer Str. 61, Berlin, 13347, Germany.
Rahel
R
Eckardt
Charité Research Group on Geriatrics, Charité-Universitätsmedizin Berlin, Reinickendorfer Str. 61, Berlin, 13347, Germany. kristina.norman@charite.de.
Kristina
K
Norman
D015502:Absorptiometry, Photon; D000368:Aged; D000375:Aging / Q000187:drug effects*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001604:Berlin; D001823:Body Composition; D015992:Body Mass Index; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D018737:Hand Strength / Q000502:physiology; D006801:Humans; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D053580:Muscle Strength / Q000187:drug effects; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000503:physiopathology; D056687:Off-Label Use; D009929:Organ Size; D012044:Regression Analysis; D012307:Risk Factors; D055948:Sarcopenia / Q000188:drug therapy* / Q000503:physiopathology
D000806:Angiotensin-Converting Enzyme Inhibitors
Gerontology. 2006;52(4):237-42
16849867
Am J Med. 1998 Jul 6;105(1A):27S-31S
9707265
J Gerontol A Biol Sci Med Sci. 2014 Jun;69(6):736-43
24201696
J Am Geriatr Soc. 2012 Dec;60(12):2206-14
23176078
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
11253156
J Gerontol A Biol Sci Med Sci. 2014 May;69(5):576-83
24737560
Age (Dordr). 2014 Feb;36(1):275-85
23818105
Lancet. 2003 Mar 29;361(9363):1077-83
12672310
JAMA. 1995 May 10;273(18):1450-6
7654275
Age Ageing. 2014 Sep;43(5):661-6
24522120
CMAJ. 2007 Oct 9;177(8):867-74
17923654
Age Ageing. 2010 Jul;39(4):412-23
20392703
Eur Heart J. 1996 Nov;17(11):1678-85
8922916
J Chronic Dis. 1987;40(5):373-83
3558716
Drugs Aging. 2015 Sep;32(9):727-35
26286094
J Am Geriatr Soc. 2004 Jun;52(6):961-6
15161462
Am J Epidemiol. 2002 Jul 15;156(2):110-21
12117699
J Am Med Dir Assoc. 2010 Jan;11(1):26-32
20129212
Am J Epidemiol. 1998 Apr 15;147(8):755-63
9554417
Curr Pharm Des. 2006;12(16):2057-64
16787247
J Am Geriatr Soc. 1991 Feb;39(2):142-8
1991946
Maturitas. 2013 Jan;74(1):79-83
23200514
Lancet. 2002 Mar 16;359(9310):926-30
11918911
Diabetes. 2006 Jun;55(6):1813-8
16731847
J Gerontol A Biol Sci Med Sci. 2015 Jun;70(6):779-84
25638537
J Am Geriatr Soc. 2007 Nov;55(11):1712-9
17979895
J Gerontol A Biol Sci Med Sci. 2014 May;69(5):567-75
24737559
Endocrinology. 2001 Apr;142(4):1489-96
11250929
J Nutr Health Aging. 2008 Aug-Sep;12(7):480-5
18615230
Clin Geriatr Med. 2011 Aug;27(3):423-47
21824556
J Am Med Dir Assoc. 2011 May;12(4):249-56
21527165
Psychol Aging. 2015 Jun;30(2):301-10
25799003
Int J Epidemiol. 2014 Jun;43(3):703-12
23505255
J Cachexia Sarcopenia Muscle. 2014 Sep;5(3):239-46
24614996
J Gerontol A Biol Sci Med Sci. 2013 Feb;68(2):168-74
22503991
J Am Coll Cardiol. 2002 Mar 6;39(5):767-75
11869839